

# Platelet Serotonin Level: An Essential Role in Human Behavior, Stress Reaction and the Selection of Psychotropic Drugs

Dr. Devasis Ghosh<sup>1</sup>, Anindita Guha<sup>2</sup>

<sup>1</sup>Sr. Consultant in Mental Health, Calcutta University, 2/48 Naktala, Kolkata 700047, WB, India

<sup>2</sup>Vivekananda B. Ed & D. El. Ed. College, Calcutta University, 1/23a Azadgarh road Kolkata 700040, WB, India

**Abstract:** Platelet serotonin level in blood is pre-determined genetically & is grossly influenced by the individual's Stress reactions. This in turn inversely influences the level of Dopamine in blood. Serotonin and dopamine then both act together in the causation of different behavioral patterns after any stressful stimulus. The purpose of this study was to prove: i) Significance of Platelet serotonin level estimation as a prerequisite to diagnosis and treatment of Stress. ii) Importance of considering simultaneously symptoms of both Serotonin and Dopamine levels in blood for proper choice of medication. Some basic data and information collected from subjects having mental stress (Perceived Stress Scale score 27 - 40). Platelet serotonin levels were estimated. Subjects were then divided into two groups having a) Low Platelet Serotonin levels and b) High Platelet Serotonin levels. Fifteen case studies from each group were done. Treatments were started or modified accordingly and reviewed after 2 weeks. This study shows that both high and low values of Platelet serotonin may act as a biochemical stress marker. Subjects with high serotonin level also showed symptoms of low dopamine and vice versa. So it can be concluded that Platelet serotonin level in blood should be a routine test for any stress reaction. Symptoms of both Serotonin and Dopamine levels should be considered simultaneously, to help in the rational choice of medication. Empirical use of anti-depressants in high platelet serotonin cases may cause Serotonin syndrome.

**Keywords:** Mental Stress; Platelet Serotonin; Dopamine; Stress bio - marker; Anti depressants, Serotonin syndrome

## 1. Introduction

Mental stress is a universal human state of mind with a widespread prevalence, regardless of age, sex, ethnicity and religion. Strangely only antidepressants, alone or in combination with long-term benzodiazepines / hypnotics, have been increasingly used in recent years around the world. (Parish, 1971; Knapp et al.2007; Chen et al.2008; Johnson et al.2014) though research shows antidepressants only reduce depression symptoms by 20% after 6 - 8 weeks when compared to placebo. (*Inform. Educ.*2006 - - , Depression: How effective are antidepressants). Serotonin (5HT), one of the neurotransmitters, having an immense role in some fundamental aspects of human physiology and behavior (Jacobs, 1994) is able to cross blood brain barrier under stressful conditions and the changes in central or neuronal 5HT corresponds highly to 5HT level in platelets (Cohen et al.1999; Huber et al.2001; Bianchi et al.2002; Oztas et al.2004) Again this serotonin system has been found to have an antagonistic action with dopamine system, according to anatomical and pharmacological studies. (Wong et al.1995; Daw et al.2002). So it would be prudent to measure platelet serotonin level from blood in all cases of mental stress and also to consider the symptoms of both Serotonin and Dopamine levels simultaneously for the proper choice of psychotropic drugs in its management.

Platelet serotonin' has been recommended as an appropriate peripheral model of central neuronal activities (Sneddon, 1973;) because neurons and platelets have structural and functional similarities, share a similar serotonin uptake & release mechanism and platelets store more than 99% of serotonin in blood. (Camacho & Dimsdale, 2000; Barišić et al.2004; Newport et al.2004). The level of serotonin in the

brain is both genetically predetermined within some range and may also be influenced by social interactions and experience. (Wright, 1995)

Platelet serotonin level in blood has an immense effect on the behavioral pattern of the person. Reduced platelet serotonin level has been shown to be associated with aggressive behavior, Impulsive behavior (Seo & Patrick, 2008), Non psychotic depression (Parsey et al.2006), Non paranoid schizophrenia (Muck - Seler, 1991), Panic disorder (Deakin & Graeff, 1991; Bell & Nutt, 1998) increased irritability, Self harm, (Dutta et al.2017), Suicidal tendency (Mann, 1990) OCD (Baumgarten & Grozdanovic, 1998), Autism spectrum disorder. (Spivak et al.2004; Oblak et al.2013; Daly et al.2014). Whereas increased Platelet Serotonin levels in blood has been shown to be associated with various behavioral disorders: Panic disorder (Iversen, 1984; Kahn et al.1988; Kahn et al.1988), severe aggression (Mann et al.1992), Psychosis, Paranoid schizophrenia, psychotic depression (Mück - Seler, 1991), bipolar (Shiah, 1999) inhibition of impulsive behavior (Miyazaki & Doya 2012)

Serotonin and dopamine are both antagonistic to each other. High levels of serotonin appears to inhibit dopamine production in some situations. Inversely low levels of serotonin will lead to an overproduction of Dopamine. (Seo et al.2008) Moreover, Serotonin (5 HT) 2 receptors inhibit Dopamine (DA) activity, and so 5 HT2 receptor antagonists counteract this inhibitory effect on the DA activity and may increase dopamine levels. (Sorensen et al.1993; Shi et al.1995; Milan et al.1998).

So it can be inferred that Serotonin and dopamine both may act together in the causation of different behavioral patterns

Volume 12 Issue 7, July 2023

[www.ijsr.net](http://www.ijsr.net)

Licensed Under Creative Commons Attribution CC BY

after any stressful stimulus. As an example. with Low Serotonin level, subjects may have one or more of the High Dopamine symptoms e. g.: Addiction, [Some studies show the use of dopaminergic antagonists in alcohol dependence] (Volkow et al.2007; Martinotti et al.2007; Kampman et al.2007; Bender et al.2007; Martinotti et al.2009), High Sexual drive (Sanna et al.2020), OCD (Denys et al.2004; Koo et al.2010), poor impulse control and aggression (Seo et al.2008), Gambling (Meyer et al.2004; Voon et al.2009), Improved ability to focus & learn, enhanced confidence & motivation, (Lou et al.2011) Mania, Difficulty in sleeping, Competitive attitude, Binge eating bouts, Hallucinations, Schizophrenia and Delusions (Laruelle & Abi - Dargham 1999; Howes et al.2009)

Similarly with High Serotonin level, subjects may have one or more of the Low dopamine symptoms: Low self esteem, trouble sleeping or disturbed sleep (Blum et al.2014), low

energy, inability to focus, ADHD (Gold et al.2014), lack of drive & motivation, hopelessness, low mood (Diehl & gershon, 1992), anxiety, self harm (Breese et al.1989) suicidal (Roy et al.1992; Pitchot et al.2001), low sex drive (Graf et al.2019), hallucinations & delusions (Tost et al.2010), lack of insight/self - awareness. (Cadman 2018). These symptoms have been summarized in Table 1.

Moreover due to stigma and a lack of reliable diagnoses, they are frequently under diagnosed, undertreated, and can lead to self - medication with alcohol and narcotics and may even lead to violence and suicide in certain cases. (Shaler et al.2017; Sharma & Ressler 2019; Stein & Rothbaum 2018; Le - Niculescu et al.2020). Therefore measurement of Platelet serotonin and consideration of symptoms of both serotonin & dopamine are two essential steps towards rational choice of proper psychotropic drug in cases of mental stress.

Table 1

<p><b>LOW SEROTONIN LEVEL symptoms</b></p> <p>Impulsive behavior Aggression Increased irritability Non psychotic depression, Non paranoid schizophrenia Panic disorder DSH Suicidal tendency Autism spectrum disorder OCD</p>	<p><b>HIGH DOPAMINE LEVEL symptoms</b></p> <p>Poor impulse control Aggression Schizophrenia, Hallucinations, Delusions Improved ability to focus &amp; learn Enhanced motivation, Competitive Mania, Difficulty in sleeping Addiction Gambling Binge eating, High Sexual drive OCD</p>
<p><b>HIGH SEROTONIN LEVEL symptoms</b></p> <p>Severe aggression Panic disorder Inhibition of impulsive behavior Paranoid Schizophrenia Psychotic depression Bipolar Depression Psychosis</p>	<p><b>LOW DOPAMINE LEVEL symptoms</b></p> <p>Low self esteem Lack of drive/motivation Hopelessness Low energy Inability to focus ADHD Disturbed Sleep Anxiety Low sex drive DSH, Suicidal Hallucinations Delusions Lack of insight/self - awareness</p>

**Objectives**

Till date there are no proven biochemical markers to help the clinicians to understand a person’s unique stress reactions and its treatment.

This study intends to establish:

- 1) Significance of Platelet serotonin level estimation as a prerequisite to the proper understanding and treatment of Stress reaction,
- 2) Importance of considering simultaneously symptoms of both Serotonin and Dopamine levels in blood.

**2. Methodology**

Self made questionnaires cum observation schedule were developed to collect basic data from 50 subjects having behavioral problems after one or more mental stressful

events in their lives. All of them were administered 14 - item Perceived Stress Scale (Cohen et al.1983) for assessment rating of stress, average score of chosen subjects were in the range 27 - 40 indicating high perceived stress.

Serotonin ElisaKit (Demeditec Diagnostics, Germany) was used to measure Platelet serotonin level from blood and compared with normal subjects. Normal value in Pulse Diagnostic Lab. in Kolkata, India is 100 – 200 ng/ 10<sup>9</sup> platelets.

Then subjects were categorized into two groups having either High platelet serotonin level or Low platelet serotonin level. Fifteen case studies from each group were done and their symptoms or complaints were compared. Treatments were started/ altered according to platelet serotonin levels. Any improvements in symptoms were reviewed after 2 weeks.

3. Results

Estimation of random sampling of 50 subjects with mental stress (PSS score 27 - 40) were done. This study found that stress may even lead to low platelet serotonin levels though it is known that after any mental stressful stimuli, usually release of serotonin increased in plasma from activated platelets.1) Therefore we can infer that both high and low values of Platelet serotonin may act as a biochemical marker for Mental Stress.

Fifteen subjects from each group of high platelet serotonin and low platelet serotonin level, were chosen to study their behavioral symptoms. It was found that: i) Subjects having Low platelet serotonin level also showed of one or more symptoms of high dopamine level. ii) Similarly subjects having High platelet serotonin level showed one or more symptoms of low dopamine level.2) So it would be rational to consider the symptoms of both serotonin and dopamine

levels together while taking proper history of any patient of mental stress.

From this study it was also found that: a) Subjects with low platelet serotonin level did not respond to SSRI alone. Drugs acting on high Dopamine levels were started along with SSRI. b) Subjects with high platelet serotonin, did not respond to SSRI (along with anti psychotics in some cases). SSRI were stopped and serotonin receptor antagonists were given along with dopamine receptor agonists for better control of symptoms. Improvement in symptoms or behavioral patterns were noted within a very short period of 2 weeks.3) Hence, this study did help in the choice/alteration of psychotropic drugs and improvements in symptoms were noticed within 2 weeks of treatment.

As a sample, detailed complaints, history and treatment of only 5 case studies in each category of Low Platelet Serotonin and High Platelet Serotonin, are given below, in Table 2.

Table 2: Low Serotonin – High Dopamine Cases

Age/ Sex	Presenting Complaint	Other clinical features	Duration of illness & Stressful Factor	Past Psychiatric treatment	Platelet serotonin level ng/10 <sup>9</sup>	Treatment given	Improvement within 2 weeks
30M	Anxiety	Impulsive aggression Cannabis Addiction	>4 years Dominating Mother Disturbed distance Relationship	SSRI only	45.92	Added Flupenthixol 0.5 mg	Marked improvement in aggression, Anxiety Reduced urge for cannabis
42F	Aggression Anxiety	Impulsive Competitive	>3 years Disharmony relationship Stressed about younger daughter	None	1.14	SSRI + Flupenthixol	Improvement noticed within 2 weeks
42M	Phobia	Social Anxiety, depression, paranoia	>2 years Abusive parents	SSRI	0.02	Added Flupenthixol 0.5 mg	Marked improvement within 2 weeks
23M	Social anxiety, Irritability	Impulsively aggressive,	>2 years Stressed about career	Prodep (SSRI)	12.43	Added Amisulpride	Marked improvement
28F	Depression, Anxiety	Paranoid delusion about a vaginal rash, PCOS	>6 months	SSRI	0.02	Added Amisulpride	Improved

High Serotonin – Low Dopamine Cases

Age/ Sex	Presenting Complaint	Other clinical features	Duration of illness & Stressful Factor	Past Psychiatric treatment	Platelet serotonin level ng/10 <sup>9</sup>	Treatment Given	Improvement within 2 weeks
46F	Severe aggression Irrelevant talk	Lack of motivation Decreased libido	>3 years Death of Father in childhood Over - possessive dominating mother	Olanzapine 10 mg daily once only	685.98	Valproic acid 500 mg BD added	Marked improvement in Aggression, no more irrelevant talking, Motivation to work improved, libido improved.
44M	Auditory hallucination	Aggression decreased libido	>6 months Stressed with local residents bad & irrational behavior	SSRI	304.69	Stopped SSRI, started *Olanzapine & Levecitaram	Responded well within 2 weeks
48M	Lack of motivation Decreased libido	Lack of concentration having low self esteem disturbed sleep	>2 years Stressed about mother's death	SSRI	815.68	Stopped SSRI Started *Amisulpride *Lamitrogine	Improved well within 2 weeks
24F	Aggression, Sibling jealousy Suicidal	Paranoid, lack of motivation. obsessed with her hair	Stressed about Mathematics from Class V - - VIII	SSRI + aripiprazol	845.8	SSRI stopped Started on Lamitrogine & Rispiradone	Improved well within 2 weeks
60F	Aggression, Hallucination	Disturbed sleep, low libido	>3 years Stressed about sons	SSRI+ Antipsychotics	560.8	SSRI stopped Valproic acid added	Improved markedly within 2 weeks

#### 4. Discussion & Implications

Platelet serotonin level estimation test may be done in any patient suffering from mental stress showing behavioral abnormalities. This test also may help to remove stigma of treatment in mental health in non - willing subjects.

While observing and treating patients with high and low serotonin levels, it is indicative that they may have low and high dopamine levels respectively. These results have been supported by several previous research studies (Wong et al.1995; Daw et al.2002; Seo et al.2008).

Therefore it is important to consider the symptoms of both serotonin and dopamine levels together while taking proper history of any patient of mental stress and treat accordingly, e. g. non psychotic depression with addiction and high sexual drive, where the platelet serotonin is found very low, may not respond to SSRI only. The other symptoms may be due to the accompanied high dopamine level which needs to be treated at the same time.

Similarly, patient having severe aggression with lack of drive or motivation, where serotonin level is found high, low dopamine level factor has to be taken also into consideration and treat accordingly.

In patients, where the platelet serotonin is already high, empirical use of anti - depressants as the drug of first choice in mental stress may further raise serotonin level which may be more detrimental and may cause 'Serotonin Syndrome' in a some cases.

#### 5. Conclusion

This study proves the importance of measuring platelet serotonin level in blood, for proper understanding of abnormal human behavior in mental stress, the relevance of considering simultaneously symptoms of both Serotonin and Dopamine levels, for rational choice of psychotropic drugs. This study may help to reduce the empirical use of anti - depressants as the drug of first choice in any stress reaction as this may lead to potentially fatal 'Serotonin syndrome' logically in high serotonin level cases. Whether this platelet serotonin test will be accepted as a routine blood test is a separate discussion but the evidence suggests that by doing so could lead to a future where stress reactions and other abnormal human behavioral patterns can be treated more efficiently and rationally.

#### Acknowledgement

No financial support was taken for this study. Informed consent was taken from each and every subject taking part in this study.

#### References

- [1] *A global measure of perceived stress.* (1983, December 1). PubMed. —<https://pubmed.ncbi.nlm.nih.gov/6668417/>
- [2] *APA PsycNet.* (n. d.). <https://psycnet.apa.org/record/1998-04425-003>

- [3] Barišić, I., Pivac, N., Muck - Seler, D., Jakovljević, M., & Šagud, M. (2004). Comorbid Depression and Platelet Serotonin in Hemodialysis Patients. *Nephron Clinical Practice*, 96 (1), c10–c14. <https://doi.org/10.1159/000075566>
- [4] Baumgarten, H. G., & Grozdanovic, Z. (1998). Role of serotonin in obsessive–compulsive disorder. *British Journal of Psychiatry. Supplement*, 35 (35), 13–20. <https://doi.org/10.1192/S0007125000297857>
- [5] Bell, C. J., & Nutt, D. J. (1998). Serotonin and panic. *British Journal of Psychiatry*, 172, 465–471. <https://doi.org/10.1192/bjp.172.6.465>
- [6] Bender, S., Scherbaum, N., Soyka, M., Rütger, E., Mann, K., & Gastpar, M. (2007). The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: A randomised, double-blind, placebo-controlled trial in 299 alcohol-dependent patients. *International Journal of Neuropsychopharmacology*, 10 (5), 653–660. <https://doi.org/10.1017/S1461145706007164>
- [7] Bianchi, M., Moser, C., Lazzarini, C., Vecchiato, E., & Crespi, F. (2002). Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5 - HT in rat platelet - rich plasma mirrors cerebral extracellular 5 - HT levels, whilst 5 - HT in isolated platelets mirrors neuronal 5 - HT changes. *Experimental Brain Research*, 143 (2), 191–197. <https://doi.org/10.1007/s00221-001-0979-3>
- [8] Blum, K., Oscar - Berman, M., Badgaiyan, R. D., Khurshid, K. A., & Gold, M. S. (2014). Dopaminergic Neurogenetics of Sleep Disorders in Reward Deficiency Syndrome (RDS). *NIH NLM*, 03 (02). <https://doi.org/10.4172/2167-0277.1000e126>
- [9] Breese, G. R., Criswell, H. E., Duncan, G. E., & Mueller, R. A. (1989). Dopamine deficiency in self - injurious behavior. *Psychopharmacology Bulletin*, 25 (3), 353–357.
- [10] Camacho, A., & Dimsdale, J. E. (2000). Platelets and Psychiatry: Lessons Learned From Old and New Studies. *Psychosomatic Medicine*, 62 (3), 326–336. <https://doi.org/10.1097/00006842-200005000-00006>
- [11] Cadman, B. (2018, January 17). Dopamine deficiency: What you need to know. Medical news today. <https://www.medicalnewstoday.com/articles/320637.php>
- [12] *Characterization of the 5 - HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.* (1993, August 1). PubMed. <https://pubmed.ncbi.nlm.nih.gov/8102646/>
- [13] Chen, Y., Kelton, C. M., Jing, Y., Guo, J. J., Li, X., & Patel, N. C. (2008). Utilization, price, and spending trends for antidepressants in the US Medicaid program. *Research in Social & Administrative Pharmacy*, 4 (3), 244–257. <https://doi.org/10.1016/j.sapharm.2007.06.019>
- [14] Cohen, Z., Bouchelet, I., Olivier, A., Villemure, J. G., Ball, R., Stanimirovic, D. B., & Hamel, E. (1999, August). Multiple microvascular and astroglial 5 - hydroxytryptamine receptor subtypes in human brain: Molecular and pharmacologic characterization. *Journal of Cerebral Blood Flow and Metabolism*, 19

- (8), 908–917. <https://doi.org/10.1097/00004647-199908000-00010>
- [15] Cohen, S., Kamarck, T., & Mermelstein, R. (1983, December). A global measure of perceived stress. *Journal of Health and Social Behavior*, 24 (4), 385–396. <https://doi.org/10.2307/2136404>
- [16] Daw, N. D., Kakade, S. M., & Dayan, P. (2002). Opponent interactions between serotonin and dopamine. *Neural Networks*, 15 (4–6), 603–616. [https://doi.org/10.1016/s0893-6080\(02\)00052-7](https://doi.org/10.1016/s0893-6080(02)00052-7)
- [17] Daly, E., Ecker, C., Hallahan, B., Deeley, Q., Craig, M., Murphy, C. M., Johnston, P. B., Spain, D., Gillan, N., Gudbrandsen, M., Brammer, M., Giampietro, V., Lamar, M., Page, L., Toal, F., Schmitz, N., Cleare, A. J., Robertson, D., Rubia, K., & Murphy, D. G. (2014). Response inhibition and serotonin in autism: a functional MRI study using acute tryptophan depletion. *Brain*, 137 (9), 2600–2610. <https://doi.org/10.1093/brain/awu178>
- [18] Deakin, J. F. W., & Graeff, F. G. (1991). HT and mechanisms of defence. *Journal of Psychopharmacology*, 5 (4), 305–315. <https://doi.org/10.1177/026988119100500414>
- [19] Denys, D., Zohar, J., & Westenberg, H. G. (2004) - psychiatrist. com. The role of dopamine in obsessive–compulsive disorder: Preclinical and clinical evidence. *Journal of Clinical Psychiatry*
- [20] Diehl, D. L., & Gershon, S. (1992). The role of dopamine in mood disorders. *Comprehensive Psychiatry*, 33 (2), 115–120. [https://doi.org/10.1016/0010-440x\(92\)90007-d](https://doi.org/10.1016/0010-440x(92)90007-d)
- [21] *Dopamine deficiency in self - injurious behavior*. (1989). PubMed. <https://pubmed.ncbi.nlm.nih.gov/2697009/>
- [22] Dutta, S., Gupta, S., Raju, M. V. L. N., Kumar, A., & Pawar, A. (2017). Platelet Serotonin Level and Impulsivity in Human Self - destructive Behavior: A Biological and Psychological Study. *Journal of Neurosciences in Rural Practice*, 08 (02), 199–203. [https://doi.org/10.4103/jnrp.jnrp\\_425\\_16](https://doi.org/10.4103/jnrp.jnrp_425_16)
- [23] Gold, M. S., Blum, K., Oscar - Berman, M., & Braverman, E. R. (2014). Low Dopamine Function in Attention Deficit/Hyperactivity Disorder: Should Genotyping Signify Early Diagnosis in Children? *Postgraduate Medicine*, 126 (1), 153–177. <https://doi.org/10.3810/pgm.2014.01.2735>
- [24] Graf, H., Malejko, K., Metzger, C. D., Walter, M., Grön, G., & Abler, B. (2019). Serotonergic, Dopaminergic, and Noradrenergic Modulation of Erotic Stimulus Processing in the Male Human Brain. *Journal of Clinical Medicine*, 8 (3), 363. <https://doi.org/10.3390/jcm8030363>
- [25] Howes, O. D., & Kapur, S. (2009). The Dopamine Hypothesis of Schizophrenia: Version III - - The Final Common Pathway. *Schizophrenia Bulletin*, 35 (3), 549–562. <https://doi.org/10.1093/schbul/sbp006>
- [26] Huber, J. C., Witt, K. A., Hom, S., Egleton, R. D., Mark, K. S., & Davis, T. P. (2001). Inflammatory pain alters blood - brain barrier permeability and tight junctional protein expression. *American Journal of Physiology - heart and Circulatory Physiology*, 280 (3), H1241–H1248. <https://doi.org/10.1152/ajpheart.2001.280.3.h1241>
- [27] *Inform. Educ.* (2006–). Depression: How effective are antidepressants? Last Update: June 18, 2020. Cologne, Germany: Institute for quality and efficiency in health care (IQWiG). Health. org [Internet].
- [28] Iversen, S. D. (1984). HT and anxiety. *Neuropharmacology*, 23 (12B), 1553–1560. [https://doi.org/10.1016/0028-3908\(84\)90099-6](https://doi.org/10.1016/0028-3908(84)90099-6)
- [29] J. M. Sneddon, “Blood Platelets as a Model for Mono - amine Containing Neurones, ” *Progress in Neurobiology*, Vol.1, No.2, 1973, pp.151 - 198. - *References - Scientific Research Publishing.* (n. d.). <https://www.scirp.org/> (S (351jmbntvnsjtladkposzje)) /reference/ReferencesPapers.aspx?ReferenceID=48366
- [30] Jacobs, B. (1994, January 1). *Serotonin, motor activity and depression - related disorders*. Princeton University. [https://collaborate.princeton.edu/en/publications/serotonin - motor - activity - and - depression - related - disorders](https://collaborate.princeton.edu/en/publications/serotonin-motor-activity-and-depression-related-disorders)
- [31] Johnson, C. A., Dougall, N., Williams, B. G., MacGillivray, S., Buchanan, A. I., & Hassett, R. D. (2014). Patient factors associated with SSRI dose for depression treatment in general practice: a primary care cross sectional study. *BMC Family Practice*, 15 (1). <https://doi.org/10.1186/s12875-014-0210-9>
- [32] Kahn, R. S., Asnis, G. M., Wetzler, S., & Van Praag, H. M. (1988). Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. *Psychopharmacology*, 96 (3), 360–364. <https://doi.org/10.1007/bf00216062>
- [33] Kahn, R., Wetzler, S., Van Praag, H. M., Asnis, G. M., & Strauman, T. J. (1988). Behavioral indications for serotonin receptor hypersensitivity in panic disorder. *Psychiatry Research - neuroimaging*, 25 (1), 101–104. [https://doi.org/10.1016/0165-1781\(88\)90163-1](https://doi.org/10.1016/0165-1781(88)90163-1)
- [34] Kampman KM, O’Brien CP, Sparkman T, Oslin DW, Tirado C, Dackis C, Macfadden W, Whittingham T, Lynch KG, & Pettinati HM. (2007). *A double - blind, placebo - controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism*. Europe PMC. <https://europepmc.org/article/MED/17632217>
- [35] Kellner, M. (2010). Drug treatment of obsessive - compulsive disorder. *Dialogues in Clinical Neuroscience*, 12 (2), 187–197. <https://doi.org/10.31887/dcns.2010.12.2/mkellner>
- [36] Knapp, M., McDavid, D., Mossialos, E., & Thornicroft, G. (2007). *Mental health policy and practice across Europe: The future direction of mental health care*. McGraw - Hill, Open University Press.
- [37] Koo, M., Kim, E. K., Roh, D., & Kim, C. (2010). Role of dopamine in the pathophysiology and treatment of obsessive–compulsive disorder. *Expert Review of Neurotherapeutics*, 10 (2), 275–290. <https://doi.org/10.1586/ern.09.148>
- [38] Laruelle, M., & Abi - Dargham, A. (1999). Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. *Journal of Psychopharmacology*, 13 (4), 358–371. <https://doi.org/10.1177/026988119901300405>
- [39] Le - Niculescu, H., Roseberry, K., Levey, D. F., Rogers, J. A., Kosary, K., Prabha, S., Jones, T., Judd, S. J., McCormick, M. P., Wessel, A. R., Williams, A.

- M., Phalen, P., Mamdani, F., Sequeira, A., Kurian, S. M., & Niculescu, A. B. (2019). Towards precision medicine for stress disorders: diagnostic biomarkers and targeted drugs. *Molecular Psychiatry*, 25 (5), 918–938. <https://doi.org/10.1038/s41380-019-0370-z>
- [40] Lou, H. C., Skewes, J., Thomsen, K. M., Rees, G., Lau, H., Mouridsen, K., & Roepstorff, A. (2011). Dopaminergic stimulation enhances confidence and accuracy in seeing rapidly presented words. *Journal of Vision*, 11 (2), 15. <https://doi.org/10.1167/11.2.15>
- [41] Mann, J. J., Arango, V., & Underwood, M. A. (1990). Serotonin and Suicidal Behavior. *Annals of the New York Academy of Sciences*, 600 (1 The Neurophar), 476–484. <https://doi.org/10.1111/j.1749-6632.1990.tb16903.x>
- [42] Mann, J. J., McBride, P., Anderson, G. M., & Mieczkowski, T. A. (1992). Platelet and whole blood serotonin content in depressed inpatients: Correlations with acute and life - time psychopathology. *Biological Psychiatry*, 32 (3), 243–257. [https://doi.org/10.1016/0006-3223\(92\)90106-a](https://doi.org/10.1016/0006-3223(92)90106-a)
- [43] Martinotti, G., Di Nicola, M., Di Giannantonio, M., & Janiri, L. (2008). Aripiprazole in the treatment of patients with alcohol dependence: a double - blind, comparison trial vs. Naltrexone. *Journal of Psychopharmacology*, 23 (2), 123–129. <https://doi.org/10.1177/0269881108089596>
- [44] Martinotti, G., Di Nicola, M., & Janiri, L. (2007). Efficacy and Safety of Aripiprazole in Alcohol Dependence. *American Journal of Drug and Alcohol Abuse*, 33 (3), 393–401. <https://doi.org/10.1080/00952990701313660>
- [45] Martinotti, G., Di Nicola, M., Di Giannantonio, M., & Janiri, L. (2009). Aripiprazole in the treatment of patients with alcohol dependence: A double-blind, comparison trial vs. naltrexone. *Journal of Psychopharmacology*, 23 (2), 123–129. <https://doi.org/10.1177/0269881108089596>
- [46] *Mental health policy and practice across Europe: the future direction of mental health care.* (n. d.). <https://eurohealthobservatory.who.int/publications/m/mental-health-policy-and-practice-across-europe-the-future-direction-of-meantial-health-care>
- [47] Meyer, G., Schwertfeger, J., Exton, M. S., Janssen, O. E., Knapp, W. H., Stadler, M. B., Schedlowski, M., & Frieling, H. (2004). Neuroendocrine response to casino gambling in problem gamblers. *Psychoneuroendocrinology*, 29 (10), 1272–1280. <https://doi.org/10.1016/j.psyneuen.2004.03.005>
- [48] Millan, M., Dekeyne, A., & Gobert, A. (1998). Serotonin (5 - HT) 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5 - HT, release in the frontal cortex in vivo. *Neuropharmacology*, 37 (7), 953–955. [https://doi.org/10.1016/s0028-3908\(98\)00078-1](https://doi.org/10.1016/s0028-3908(98)00078-1)
- [49] Miyazaki, K. W., & Doya, K. (2012). The Role of Serotonin in the Regulation of Patience and Impulsivity. *Molecular Neurobiology*, 45 (2), 213–224. <https://doi.org/10.1007/s12035-012-8232-6>
- [50] Mph, Z. S. (2023, June 12). *Dopamine deficiency: What you need to know.* <https://www.medicalnewstoday.com/articles/320637>
- [51] Muck - Seler, D., Jakovljević, M., & Deanovic, Z. (1991). Platelet serotonin in subtypes of schizophrenia and unipolar depression. *Psychiatry Research - neuroimaging*, 38 (2), 105–113. [https://doi.org/10.1016/0165-1781\(91\)90036-o](https://doi.org/10.1016/0165-1781(91)90036-o)
- [52] Newport, D. J., Owens, M. J., Knight, D. W., Ragan, K., Morgan, N., Nemeroff, C. B., & Stowe, Z. N. (2004). Alterations in platelet serotonin transporter binding in women with postpartum onset major depression. *Journal of Psychiatric Research*, 38 (5), 467–473. <https://doi.org/10.1016/j.jpsychires.2004.01.011>
- [53] Oblak, A. L., Gibbs, T. T., & Blatt, G. J. (2013). Reduced Serotonin Receptor Subtypes in a Limbic and a Neocortical Region in Autism. *Autism Research*, 6 (6), 571–583. <https://doi.org/10.1002/aur.1317>
- [54] Öztaş, B., Akgül, S., & Arslan, F. (2004). Influence of surgical pain stress on the blood - brain barrier permeability in rats. *Life Sciences*, 74 (16), 1973–1979. <https://doi.org/10.1016/j.lfs.2003.07.054>
- [55] Parish, P. A. (1971). The prescribing of psychotropic drugs in general practice. *Journal of the Royal College of General Practitioners*, 21 (92) (Suppl.4), 1–77. <https://pubmed.ncbi.nlm.nih.gov/5143711/>
- [56] Parsey, R. V., Hastings, R. S., Oquendo, M. A., Huang, Y., Simpson, N. R., Arcement, J., Huang, Y., Ogden, R., Van Heertum, R. L., Arango, V., & Mann, J. J. (2006). Lower Serotonin Transporter Binding Potential in the Human Brain During Major Depressive Episodes. *American Journal of Psychiatry*, 163 (1), 52–58. <https://doi.org/10.1176/appi.ajp.163.1.52>
- [57] Pitchot, W., Hansenne, M., & Anseau, M. (2001). Role of dopamine in non - depressed patients with a history of suicide attempts. *European Psychiatry*, 16 (7), 424–427. [https://doi.org/10.1016/s0924-9338\(01\)00601-0](https://doi.org/10.1016/s0924-9338(01)00601-0)
- [58] *Ritanserin, a 5 - HT2A/2C antagonist, reverses direct dopamine agonist - induced inhibition of midbrain dopamine neurons.* (1995, August 1). PubMed. <https://pubmed.ncbi.nlm.nih.gov/7636736/>
- [59] *Role of serotonin in obsessive - compulsive disorder.* (1998). PubMed. <https://pubmed.ncbi.nlm.nih.gov/9829022/>
- [60] Roy, A., Karoum, F., & Pollack, S. (1992). Marked Reduction in Indexes of Dopamine Metabolism Among Patients With Depression Who Attempt Suicide. *Archives of General Psychiatry*, 49 (6), 447. <https://doi.org/10.1001/archpsyc.1992.01820060027004>
- [61] Sanna, F., Bratzu, J., Serra, M. P., Leo, D., Quartu, M., Boi, M., Espinoza, S., Gainetdinov, R. R., Melis, M. R., & Argiolas, A. (2020). Altered Sexual Behavior in Dopamine Transporter (DAT) Knockout Male Rats: A Behavioral, Neurochemical and Intracerebral Microdialysis Study. *Frontiers in Behavioral Neuroscience*, 14. <https://doi.org/10.3389/fnbeh.2020.00058>
- [62] Seo, D., Patrick, C. J., & Kennealy, P. J. (2008). Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. *Aggression and Violent Behavior*, 13 (5), 383–395. <https://doi.org/10.1016/j.avb.2008.06.003>

- [63] Shalev, A. Y., Liberzon, I., & Marmar, C. R. (2017). Post - Traumatic Stress Disorder. *The New England Journal of Medicine*, 376 (25), 2459–2469. <https://doi.org/10.1056/nejmra1612499>
- [64] Sharma, S., & Ressler, K. J. (2019). Genomic updates in understanding PTSD. *Progress in Neuro - psychopharmacology & Biological Psychiatry*, 90, 197–203. <https://doi.org/10.1016/j.pnpbp.2018.11.010>
- [65] Shi, W. X., Nathaniel, P., & Bunney, B. S. (1995). Ritanserine, a 5 - HT<sub>2A/2C</sub> antagonist, reverses direct dopamine agonist - induced inhibition of midbrain dopamine neurons. *Journal of Pharmacology and Experimental Therapeutics*, 274 (2), 735–740.
- [66] Shiah, I., Ko, H. C., Lee, J., & Lu, R. B. (1999). Platelet 5 - HT and plasma MHPG levels in patients with bipolar I and bipolar II depressions and normal controls. *Journal of Affective Disorders*, 52 (1–3), 101–110. [https://doi.org/10.1016/s0165 - 0327 \(98\) 00060 - 3](https://doi.org/10.1016/s0165 - 0327 (98) 00060 - 3)
- [67] Sneddon, J. M. (1973). Blood platelets as a model for monoamine - containing neurones. *Progress in Neurobiology*, 1 (2), 151–198. [https://doi.org/10.1016/0301 - 0082 \(73\) 90019 - 1](https://doi.org/10.1016/0301 - 0082 (73) 90019 - 1)
- [68] Sorensen, S. M., Kehne, J. H., Fadayel, G. M., Humphreys, T. M., Ketteler, H. J., Sullivan, C. K., Taylor, V. L., & Schmidt, C. J. (1993). Characterization of the 5 - HT<sub>2</sub> receptor antagonist MDL100907 as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies. *Journal of Pharmacology and Experimental Therapeutics*, 266 (2), 684–691.
- [69] Spivak, B., Golubchik, P., Mozes, T., Vered, Y., Nechmad, A., Weizman, A., & Strous, R. D. (2004). Low platelet - poor plasma levels of serotonin in adult autistic patients. *Neuropsychobiology*, 50 (2), 157–160. <https://doi.org/10.1159/000079108>
- [70] Stein, M. B., & Rothbaum, B. O. (2018). 175 Years of Progress in PTSD Therapeutics: Learning From the Past. *American Journal of Psychiatry*, 175 (6), 508–516. <https://doi.org/10.1176/appi.ajp.2017.17080955>
- [71] Tost, H., Alam, T., & Meyer - Lindenberg, A. (2010). Dopamine and psychosis: Theory, pathomechanisms and intermediate phenotypes. *Neuroscience & Biobehavioral Reviews*, 34 (5), 689–700. <https://doi.org/10.1016/j.neubiorev.2009.06.005>
- [72] Volkow, N. D. MD, Fowler, J. S. PhD, Wang, G. - J. MD, Swanson, J. M., & Telang, F. (2007). Dopamine in drug abuse and addiction results of imaging studies and treatment implications. *Archives of Neurology*, 64 (11), 1575–1579. <https://doi.org/10.1001/archneur.64.11.1575>
- [73] Volkow, N. D., Fowler, J. S., Wang, G. J., Baler, R., & Telang, F. (2009). *Imaging dopamine's role in drug abuse and addiction*. *Neuropharmacology*. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2696819/>
- [74] Voon, V., Fernagut, P., Wickens, J. R., Baunez, C., Rodriguez, M. J., Pavón, N., Juncos, J. L., Obeso, J. A., & Bezard, E. (2009). Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. *Lancet Neurology*, 8 (12), 1140–1149. [https://doi.org/10.1016/s1474 - 4422 \(09\) 70287 - x](https://doi.org/10.1016/s1474 - 4422 (09) 70287 - x)
- [75] Wong, P., Feng, H., & Teo, W. (1995). Interaction of the dopaminergic and serotonergic systems in the rat striatum: effects of selective antagonists and uptake inhibitors. *Neuroscience Research*, 23 (1), 115–119. [https://doi.org/10.1016/0168 - 0102 \(95\) 90023 - 3](https://doi.org/10.1016/0168 - 0102 (95) 90023 - 3)
- [76] Wright, R. (1995, March 6). THE BIOLOGY OF VIOLENCE. *The New Yorker*. <https://www.newyorker.com/magazine/1995/03/13/the - biology - of - violence>

### Author Profile



**Dr. Devasis Ghosh**, Sr. Consultant in Mental Health, Calcutta University, 2/48 Naktala, Kolkata 700047



**Anindita Guha**, Vivekananda B. Ed & D. El. Ed. College, Calcutta University, 1/23A, Azadgarh road Kolkata 700040